ValuEngine Downgrades PAVmed Inc. (PAVM) to Strong Sell

ValuEngine downgraded shares of PAVmed Inc. (NASDAQ:PAVM) from a sell rating to a strong sell rating in a research report sent to investors on Friday, July 28th.

Receive News & Ratings for PAVmed Inc. Daily

Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAVmed Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

PAVmed (NASDAQ PAVM) opened at 3.16 on Friday. The stock’s market cap is $42.13 million. PAVmed has a one year low of $2.54 and a one year high of $14.49. The firm has a 50-day moving average price of $3.82 and a 200-day moving average price of $4.89.

PAVmed (NASDAQ:PAVM) last posted its earnings results on Monday, August 14th. The company reported ($0.13) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.14) by $0.01. On average, equities analysts predict that PAVmed will post ($0.72) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This story was originally published by [[site]] and is owned by of [[site]]. If you are viewing this story on another domain, it was illegally copied and republished in violation of US and international copyright and trademark law. The legal version of this story can be accessed at [[permalink]].

A hedge fund recently bought a new stake in PAVmed stock. Fusion Family Wealth LLC acquired a new stake in shares of PAVmed Inc. (NASDAQ:PAVM) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 55,745 shares of the company’s stock, valued at approximately $251,000. Fusion Family Wealth LLC owned approximately 0.42% of PAVmed as of its most recent filing with the SEC. Institutional investors and hedge funds own 0.70% of the company’s stock.

About PAVmed

PAVmed Inc operates as a medical device company in the United States. Its product pipeline includes PortIO, a long-term implantable vascular access device; CarpX, a percutaneous device to treat carpal tunnel syndrome; NextCath, a self-anchoring catheter; DisappEAR: Antibiotic-eluting resorbable ear tube; NextFlo, a disposable infusion pump; and Caldus, a disposable tissue ablation device.

To view ValuEngine’s full report, visit ValuEngine’s official website.